Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the TWEAK receptor (TweakR), a protein involved in various cellular responses through its interaction with TWEAK (Fn14; TNFRSF12A). By engaging TweakR signaling and promoting antibody-dependent cell-mediated cytotoxicity (ADCC), enavatuzumab inhibits tumor growth and recruits myeloid effector cells to destroy tumor cells. It suppresses the proliferation of TweakR-positive cancer cell lines and tumorigenic models both in vitro and in vivo [1] [2].